Cancer Immunotherapy
Today, cancer immunotherapy has turned into a well-established treatment strategy for an increasing number of cancers, complementing or replacing chemotherapy. But, despite surprising clinical successes, the effectiveness and efficiency of cancer immunotherapy remains limited in some patients and further improvements are needed. While much remains to be done, existing immunotherapy drugs have demonstrated the enormous potential of harnessing the power of the immune system in the fight against cancer.
Research at CCII aims both at improving the effectivness and efficiency of existing therapeutic approaches, while also building the future of next generation treatment strategies through fundamental research in systemic immunobiology. Donations will form an increasingly important part of research funding at CCII. By donating to CCII, you personally contribute to fundamental and applied research aimed at the next generation treatments in cancer immunotherapy. Also, as a member of our growing community of supporters, your benefits will include a more immediate access to information about our latest research on the immune system and cancer immunotherapy conducted at CCII.
Donations and External Funding for CCII
Public sector research in postwar Japan has been almost entirely funded through government grants. It is only over the past decades that donations from individuals or corporations in support of basic science have been increasing. CCII has been made possible, in part, by private donations and our goal is to increase funding through external donations over time, thus enabling the center to support a diverse set of research efforts, including long-term basic science.
News
June 24, 2020
Donation by Mr. Tadashi Yanai of Fast Retailing Co. to support biomedical research at Kyoto University
Major donation by one of Japan’s foremost entrepreneurs aims at supporting groundbreaking research in cancer immunology and regenerative medicine at Kyoto University.
December 9, 2022
Donation from JCR Pharma Ltd.
Donation from JCR Pharma Ltd. to the “Tasuku Honjo Volunteer Fund” and the “Cancer Immunotherapy Research Fund” through a third-party allocation of treasury shares.
May 22, 2022
Groundbreaking Ceremony for the Bristol Myers Squibb Building, the new home for CCII
The building will be constructed based on a donation of JPY 5.5 billion (US$ 53 million) from Bristol-Myers Squibb K.K., in addition to a grant from the Japanese government.